Ceribell Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤Ceribell (CBLL) Q3 revenue $29.3 million, up 30% year over year
- ➤Full-year 2026 revenue guidance raised to $115 million-$117 million
- ➤747 active accounts, with record 35 net new customers added
- ➤Q3 gross margin reached 90%, up from 88% a year earlier
- ➤Q3 net loss widened to $21.4 million, or $0.55 per share
Expert Statements
Jane Chao, Co-founder and CEO of Ceribell
“Our third quarter results reflect new highs in account additions and utilization within our existing account base, demonstrating the strength of our core seizure business as a durable growth engine,”
Jane Chao, Co-founder and CEO of Ceribell
“With the full launch of our delirium monitoring solution and the coming introduction of our new hardware platform, we are well positioned for a pivotal 2027 as we advance our mission to establish EEG as a new vital sign.”
SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the third quarter ended September 30, 2026.
Third Quarter 2026 & Recent Highlights * Reported total revenue of $29.3 million in the third quarter of 2026, a 30% increase compared to the same period in 2025 * Ended the quarter with 747 total active accounts, adding a record 35 net new customers in the quarter * Drove double-digit year-over-year same-store utilization growth * Achieved gross margin of 90% * Announced the full launch of the Company’s delirium monitoring solution following the conclusion of its successful commercial pilot * Received U.S. Food and Drug Administration 510(k) clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis “Our third quarter results reflect new highs in account additions and utilization within our existing account base, demonstrating the strength of our core seizure business as a durable growth engine,” said co-founder and CEO Jane Chao, Ph.D. “With the full launch of our delirium monitoring solution and the coming introduction of our new hardware platform, we are well positioned for a pivotal 2027 as we advance our mission to establish EEG as a new vital sign.”
Get started
Create a free account to read the full story.